B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $117 to $155.
B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $117 to $155.